mTOR inhibitor in the treatment of Hodgkin’s lymphoma: a case report

hibitor in the treatment of Hodgkin’s lymphoma: a case report Case report (1483) Total Article Views Authors: Ibeas P, Cantos B, Provencio M. Published Date November 2011 Volume 2011:1 Pages 19 - 22 DOI: http://dx.doi.org/10.2147/BLCTT.S24910 Patricia Ibeas, Blanca Cantos, Mariano Provencio Clinical Oncology Department, Hospital Puerta de Hierro Majadahonda, Madrid, Spain Abstract: Hodgkin’s disease is curable in 90% of the cases diagnosed in early stages (I and II) and in 70% of all patients who suffer from the disease. Refractory disease occurs in 10%–15% of cases and is still a clinical challenge. Its treatment is based on intensive chemotherapy regimens with transplantation, but there are patients who relapse after transplantation who have a poor prognosis. At this point in time, there is a lack of effective treatment options with proven efficacy and there is a real need to investigate new treatment drugs with different mechanisms of action. A persistent activation of mTOR signaling has been identified in leukemia, Hodgkin’s and non-Hodgkin’s lymphoma, and multiple myeloma. Everolimus, an mTOR kinase inhibitor, is being used as an option in these cases with encouraging results. Here, the authors report their experience with a patient treated with everolimus.